![Julie Hambleton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Hambleton
Direktör/Styrelseledamot på
ERASCA, INC.
Förmögenhet: 108 900 $ per 2026-07-31
Profil
Julie Hambleton is currently an Independent Director at Erasca, Inc. since 2021, Onc.ai, Inc., and Gennao Bio, Inc. since 2021.
Formerly, Dr. Hambleton was President, Chief Executive Officer & Director at Arch Oncology, Inc. from 2020 to 2021; Director at Accent Therapeutics, Inc. from 2020 to 2021; Independent Director at IGM Biosciences, Inc. from 2018 to 2025; Independent Director at Springworks Therapeutics, Inc. from 2020 to 2025; Vice President & Head-US Medical at Bristol Myers Squibb Co. from 2016 to 2017; Chief Medical Officer & Executive Vice President at Five Prime Therapeutics, Inc. from 2015 to 2016; Associate Professor at The University of California, San Francisco from 1993 to 2003; Vice President-Clinical Development at Clovis Oncology, Inc. from 2010 to 2012; Chief Medical Officer, SVP & Head-Development at IDEAYA Biosciences, Inc. from 2018 to 2020; and Medical Director-Global Clinical Development at Genentech, Inc. from 2003 to 2010.
Education includes undergraduate studies at Duke University and a doctorate from Case Western Reserve University School of Medicine.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
ERASCA, INC. 0 % | 2026-06-26 | 6 000 ( 0 % ) | 108 900 $ | 2026-07-31 |
Aktiva positioner av Julie Hambleton
| Företag | Position | Start |
|---|---|---|
| ERASCA, INC. | Direktör/Styrelseledamot | 2021-03-29 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Direktör/Styrelseledamot | 2021-07-13 |
Onc.ai, Inc.
 Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Direktör/Styrelseledamot | - |
Tidigare kända positioner av Julie Hambleton
| Företag | Position | Slut |
|---|---|---|
| IGM BIOSCIENCES, INC. | Direktör/Styrelseledamot | 2025-08-14 |
| SPRINGWORKS THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2025-07-01 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Verkställande Direktör | 2021-04-01 |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Direktör/Styrelseledamot | 2021-03-01 |
| IDEAYA BIOSCIENCES, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2020-04-30 |
Julie Hambletons utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
88
Första gradens relationer
15
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 15 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Health Technology |
Case Western Reserve University School of Medicine
 Case Western Reserve University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEAYA Biosciences, Inc.
 IDEAYA Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as oncology-focused precision medicine company which develops and sells cancer therapeutics | Health Technology |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Accent Therapeutics, Inc.
Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Springworks Therapeutics, Inc.
 Springworks Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes medicines for nervous system disorders | Health Technology |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Technology Services |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Health Technology |
